Peptides offer new hope for the development of novel therapies against stroke. As intrinsic signaling molecules in normal cellular function, natural peptides or their mimetics are important substances for the physiological regulation of organs or cells. At the same time, they provide the specificity to develop drugs for specific functions. In addition, short, well-defined neuropeptide sequences can be used or modified directly during drug synthesis, reducing the need for further structural optimization for function. Scientists are actively developing synthetic peptides that mimic natural regulatory peptides and hormones (e.g., dynorphin A (1-8) peptide, NX210, glucagon-like peptide-1) that have the potential to improve stroke outcomes.
Fig. 1. Evolution of peptide signaling and information transfer in metazoans. (Oller-Salvia et al., 2016)
Ace Therapeutics can help academic institutions or pharmaceutical companies in the field of stroke to develop synthetic peptides that mimic natural regulatory peptides and hormones with smaller size, longer half-life for elimination from the bloodstream, and greater metabolic stability. Our team consists of experts from various scientific disciplines, including biology, chemistry, and pharmacology, providing one-stop synthetic peptide development services.
Rational Design
Combinatorial Approaches
We can test the neuroprotective and neuroregenerative properties of synthetic peptides in experimental models of stroke.
Ace Therapeutics' advanced peptide synthesis facilities and high-throughput screening platforms help clients efficiently conduct synthetic peptide development activities. Ace Therapeutics is an ideal partner for stroke drug development. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.